TWI877126B - 百日咳追加疫苗 - Google Patents

百日咳追加疫苗 Download PDF

Info

Publication number
TWI877126B
TWI877126B TW108144399A TW108144399A TWI877126B TW I877126 B TWI877126 B TW I877126B TW 108144399 A TW108144399 A TW 108144399A TW 108144399 A TW108144399 A TW 108144399A TW I877126 B TWI877126 B TW I877126B
Authority
TW
Taiwan
Prior art keywords
vaccine
amount
pertussis
present
booster vaccine
Prior art date
Application number
TW108144399A
Other languages
English (en)
Chinese (zh)
Other versions
TW202038991A (zh
Inventor
尼可拉斯 伯丁
瑪蒂娜 奧克斯
瑪莉 加里諾特
里烏 馬汀 夏邦
娜塔莉 雷文紐
元慶 劉
諾艾爾 米斯特雷塔
Original Assignee
美商賽諾菲巴斯德股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽諾菲巴斯德股份有限公司 filed Critical 美商賽諾菲巴斯德股份有限公司
Publication of TW202038991A publication Critical patent/TW202038991A/zh
Application granted granted Critical
Publication of TWI877126B publication Critical patent/TWI877126B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
TW108144399A 2018-12-05 2019-12-04 百日咳追加疫苗 TWI877126B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306621.6 2018-12-05
EP18306621 2018-12-05

Publications (2)

Publication Number Publication Date
TW202038991A TW202038991A (zh) 2020-11-01
TWI877126B true TWI877126B (zh) 2025-03-21

Family

ID=65628487

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108144399A TWI877126B (zh) 2018-12-05 2019-12-04 百日咳追加疫苗

Country Status (6)

Country Link
US (1) US20220054615A1 (enExample)
EP (1) EP3890770A4 (enExample)
JP (2) JP7605739B2 (enExample)
CN (1) CN113395977A (enExample)
TW (1) TWI877126B (enExample)
WO (1) WO2020117618A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021183533A1 (en) * 2020-03-09 2021-09-16 Dynavax Technologies Corporation Active booster immunization against tetanus, diphtheria and pertussis
CN115554395A (zh) * 2022-10-12 2023-01-03 长春百克生物科技股份公司 一种百白破复合佐剂联合疫苗

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014024026A1 (en) * 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
CN104602705A (zh) * 2012-09-06 2015-05-06 诺华股份有限公司 血清组b脑膜炎球菌和d/t/p的联合疫苗
CN104159602B (zh) * 2012-03-08 2017-10-24 葛兰素史密丝克莱恩生物有限公司 加强疫苗的含佐剂制剂
US20180296663A1 (en) * 2015-06-17 2018-10-18 Curevac Ag Vaccine composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104159602B (zh) * 2012-03-08 2017-10-24 葛兰素史密丝克莱恩生物有限公司 加强疫苗的含佐剂制剂
WO2014024026A1 (en) * 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
CN104602705A (zh) * 2012-09-06 2015-05-06 诺华股份有限公司 血清组b脑膜炎球菌和d/t/p的联合疫苗
US20180296663A1 (en) * 2015-06-17 2018-10-18 Curevac Ag Vaccine composition

Also Published As

Publication number Publication date
EP3890770A4 (en) 2022-09-28
WO2020117618A1 (en) 2020-06-11
JP7605739B2 (ja) 2024-12-24
CN113395977A (zh) 2021-09-14
EP3890770A1 (en) 2021-10-13
JP2022511511A (ja) 2022-01-31
JP2024156862A (ja) 2024-11-06
TW202038991A (zh) 2020-11-01
US20220054615A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
Locht et al. New pertussis vaccination approaches: en route to protect newborns?
DK1994139T3 (en) Live, attenuated Bordetella strain as a single dose vaccine against whooping cough.
US12440547B2 (en) Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
McCluskie et al. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants
JP2024156862A (ja) 百日咳ブースターワクチン
Mirzaei et al. The study of H. pylori putative candidate factors for single-and multi-component vaccine development
Ricci et al. Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii
JP7650871B2 (ja) 免疫原性組成物
JP6401148B2 (ja) 抗原および抗原の組み合わせ
US12409214B2 (en) Immunogenic antigens
CN113226361A (zh) 疫苗多肽组合物及方法
US20230226166A1 (en) Immunogenic Antigens
US20230104907A1 (en) Live salmonella typhi vectors engineered to express protein antigens and methods of use thereof
Virella 12 Humoral Immune Response and Its
Božić et al. An overview of current vacccines for the prophylaxis of bacterical infections Pres
Ronco et al. Adjuvants for mucosal vaccines
HK40056005A (en) Vaccine polypeptide compositions and methods